Citation Impact
Citing Papers
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
2015
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade
2022
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Cancer statistics, 2022
2022 Standout
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Cancer statistics, 2023
2023 Standout
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
2019
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Cancer statistics, 2024
2024 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
2018
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Top 10 Challenges in Cancer Immunotherapy
2020
Immunological and Clinical Effects of Vaccines Targeting p53‐Overexpressing Malignancies
2011
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Trial watch
2012
Pancreatic cancer
2020 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Hereditary Kidney Cancer Syndromes
2013
Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions
2007
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
2021
Cancer immunotherapy via dendritic cells
2012 Standout
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
2021
Trial watch
2013
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
2020
Delivery technologies for cancer immunotherapy
2019 Standout
Precision medicine in cholangiocarcinoma
2018
Immune checkpoint inhibitors in melanoma
2021
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
2017
Molecular and cellular mechanisms of liver fibrosis and its regression
2020
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
2017
Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer
2019
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
2019
Global burden of liver disease: 2023 update
2023 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
2016 Standout
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
2018
How the ageing microenvironment influences tumour progression
2019
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
2021 Standout
Harnessing innate immunity in cancer therapy
2019 Nature
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
2014
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
2019
Renal cell carcinoma
2017 Standout
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Hepatocellular carcinoma
2022 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
2020
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Head and Neck Cancer
2020 Standout
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
2021
Improving Prospects for Targeting RAS
2015
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Implications of Adnexal Invasions in Primary Extramammary Paget’s Disease: A Systematic Review
2024 Standout
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
2016
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
The Next Decade of Immune Checkpoint Therapy
2021 Nobel
Toxicities of Immunotherapy for the Practitioner
2015
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
2016
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
2016
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
2017
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Neoantigens in cancer immunotherapy
2015 StandoutScience
Whole Tumor Antigen Vaccines: Where Are We?
2015
Therapeutic cancer vaccines
2015
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance
2021
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Osama E. Rahma being referenced
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
2017
Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
2014
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
2020
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
2016
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
2011
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
2013
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
2010
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
2020
Earlier presentation and application of curative treatments in hepatocellular carcinoma
2014
Aging, immune senescence, and immunotherapy: A comprehensive review
2018
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
2014
Beyond Melanoma: Inhibiting The PD-1/PD-L1 Pathway in Solid Tumors
2016
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
2018
The Intersection between Tumor Angiogenesis and Immune Suppression
2019
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
2019
MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
2018
Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer
2005
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
2019
Mismatch repair deficiency in cholangiocarcinoma.
2018
Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
2018
Abstract 2414: Comparable effect of p53 peptide vaccine in adjuvant or pulsed on dendritic cells in ovarian cancer patients: A gynecologic oncology group study
2010